Compugen Ltd. (NASDAQ:CGEN) - Investment analysts at Jefferies Financial Group issued their Q3 2020 earnings estimates for shares of Compugen in a note issued to investors on Wednesday, October 14th. Jefferies Financial Group analyst C. Howerton expects that the biotechnology company will post earnings per share of ($0.08) for the quarter. Jefferies Financial Group currently has a "Buy" rating and a $20.00 target price on the stock. Jefferies Financial Group also issued estimates for Compugen's Q4 2020 earnings at ($0.09) EPS, FY2020 earnings at ($0.35) EPS, FY2021 earnings at ($0.43) EPS, FY2022 earnings at ($0.56) EPS, FY2023 earnings at ($0.78) EPS and FY2024 earnings at ($1.14) EPS.
Other analysts have also issued research reports about the company. SVB Leerink boosted their price target on Compugen from $15.00 to $19.00 and gave the company an "outperform" rating in a research note on Wednesday, August 19th. Oppenheimer started coverage on Compugen in a research note on Thursday, July 30th. They issued a "buy" rating and a $19.00 price target on the stock. ValuEngine raised Compugen from a "hold" rating to a "buy" rating in a research note on Thursday, October 1st. BidaskClub raised Compugen from a "hold" rating to a "buy" rating in a research note on Saturday, October 10th. Finally, Zacks Investment Research raised Compugen from a "hold" rating to a "buy" rating and set a $18.00 price objective on the stock in a research note on Tuesday, September 29th. Eleven investment analysts have rated the stock with a buy rating, Compugen has an average rating of "Buy" and an average target price of $19.56.
Shares of CGEN stock opened at $15.81 on Friday. The stock's fifty day simple moving average is $16.58 and its 200 day simple moving average is $14.88. The firm has a market cap of $1.08 billion, a price-to-earnings ratio of -41.61 and a beta of 2.76. Compugen has a one year low of $3.83 and a one year high of $19.90. Compugen (NASDAQ:CGEN) last announced its quarterly earnings results on Thursday, July 30th. The biotechnology company reported ($0.08) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.10) by $0.02.
Institutional investors have recently bought and sold shares of the business. Aigen Investment Management LP bought a new stake in shares of Compugen during the second quarter worth $1,459,000. Vident Investment Advisory LLC bought a new stake in shares of Compugen during the second quarter worth $1,556,000. California State Teachers Retirement System bought a new stake in shares of Compugen during the second quarter worth $1,219,000. ProShare Advisors LLC bought a new stake in shares of Compugen during the second quarter worth $183,000. Finally, Virtu Financial LLC bought a new stake in shares of Compugen during the second quarter worth $263,000. 57.43% of the stock is currently owned by institutional investors.
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.
Featured Story: Oversold
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
20 Stocks Analysts Can't Stop Upgrading
As you know, a single upgrade from a broker probably won't be a major game changer for any single stock. But, what if there was a stock that had been upgraded by more than 10 different brokers during the last 90 days?
If ten different brokers have all upgraded a stock within the last few months and the price hasn't skyrocketed (at least, not yet), you would want to take a pretty hard look at it.
It turns out that there are actually 20 different companies that have been upgraded or had their price target increased at least ten times during the last ninety days by more than 10 different brokers. This slideshow lists those companies.
View the "20 Stocks Analysts Can't Stop Upgrading".